IP Library › Granted Patent US 10,251,848
Granted Patent B2
US 10,251,848 · App. 15/118,864 · Granted Apr 9, 2019

Process for producing a stable low concentration, injectable solution of noradrenaline

Inventors: Augusto Mitidieri (Lugano, CH); Elisabetta Donati (Cavallasca, IT); Nicola Caronzolo (Bissone, CH)
Assignee: SINTETICA S.A.
A61K31/137A61K9/0019A61K9/08A61K47/02A61L2/0023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,848
App. No.
15/118,864
Granted
Apr 9, 2019
Kind
B2
Abstract

In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.

Claims (8)

1. A stable injectable noradrenaline solution comprising noradrenaline, a solvent, an excipient, and hydrochloric acid, wherein the amount of noradrenaline is from 0.04 to 0.2 mg/ml, the solvent is degassed or deaerated water, the excipient is NaCl, and the pH of the solution is in the range of from 3.3 to 3.6, and wherein the solution is free of preservatives and anti-oxidizing agents.

2. The stable injectable noradrenaline solution according to claim 1 , obtained by a process comprising:

a. dissolving noradrenaline and the excipient in deoxygenated or degassed water, to obtain a concentration of noradrenaline from 0.04 to 0.20 mg/ml,

b. adjusting the pH of the resulting solution by adding hydrochloric acid until a value in the range from 3.3 to 3.6 is achieved,

c. filtrating the resulting noradrenaline solution in an inert gas current,

d. distributing the noradrenaline solution in an inert gas current,

e. sterilizing the noradrenaline solution.

3. The stable injectable noradrenaline solution according to claim 1 , oxygen content is equal to or lower than 100 ppb.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2016
From: MITIDIERI, AUGUSTO; DONATI, ELISABETTA; CARONZOLO, NICOLA
To: SINTETICA S.A.
Reel/Frame 039426/0680 →
Priority Claims (1)
IT MI2014A0306 · Feb 27, 2014 · national
Continuity (1)
Related Publication 20170049720A1 · Feb 23, 2017